This Thursday, all eyes will be on the Cigna Group. The healthcare giant reports its quarterly earnings not just as another financial update, but as the inaugural report card for its new CEO, Brian Evanko. More importantly, it will offer the first tangible glimpse into a seismic strategic shift: the company’s bold move to transition its massive pharmacy benefits business toward a rebate-free model. For an industry built on the complex, often opaque mechanics of drug pricing, this is not a minor course correction. It is an attempt to fundamentally rewrite the playbook in real-time, with billions in revenue and the trust of employers and patients hanging in the balance.
The pharmacy benefits manager, or PBM, landscape has long been defined by a central tension. These entities, which act as middlemen between drug manufacturers, health plans and pharmacies, have traditionally derived significant profit from the rebates they negotiate from drugmakers. These rebates, discounts off a drug’s list price, are often partially passed back to the health plan sponsor like a large employer, while the PBM retains a portion. Critics, including employers, patients and policymakers, argue this system creates perverse incentives. It can encourage PBMs to favor higher-list-price drugs that come with bigger rebates rather than the most cost-effective therapies for patients, leaving many to face high out-of-pocket costs based on inflated list prices.
Cigna’s pivot, through its Evernorth division and its flagship PBM, Express Scripts, is a direct response to this sustained criticism. The new model, which it calls “Evernorth Value,” aims to shift the economic alignment. Instead of profiting from rebates, the company says it will derive its fees from transparent, pre-negotiated payments tied to achieving specific health outcomes and cost-saving targets for its clients. In theory, this aligns Cigna’s financial success directly with the client’s goal of lowering net drug spend and improving member health. It’s a bet that transparency itself is a marketable commodity in an era of intense scrutiny.
The immediate financial implications are profound, and Thursday’s earnings call will be a forensic examination of the early impact. Analysts at firms like Morgan Stanley and J.P. Morgan will be listening intently for any discoloration in the pharmacy segment’s margins. The transition away from rebate revenue is akin to a major retailer deciding to forgo a primary line of merchandise; the question is whether the new “product”—value-based services and transparent fees—can fill the revenue gap quickly enough. Guidance from CEO Brian Evanko and his team on the pace of client adoption and the model’s impact on full-year 2025 earnings will be the core of the narrative.
This strategic gamble doesn’t exist in a vacuum. It arrives amid unprecedented political and regulatory pressure on the entire PBM industry. The Federal Trade Commission has an ongoing, sweeping investigation into PBM business practices focusing on these very rebate structures and their effect on drug prices. In Congress, bipartisan proposals aim to mandate greater transparency and clamp down on certain rebating practices. From my conversations with policy analysts in Washington, Cigna’s move is seen as a preemptive strike—an attempt to get ahead of potential mandates and shape the future regulatory environment from a position of leadership rather than defensiveness.
The human element, as always in healthcare, is critical. For the average American with a prescription, the promise is simpler: a more predictable out-of-pocket cost. If the model works as intended, patients should see co-pays based on a drug’s net price rather than its artificially high list price. But the transition is a massive operational undertaking. It requires renegotiating contracts with countless drug manufacturers and retooling complex billing systems. Any misstep could cause confusion at the pharmacy counter, eroding the very trust Cigna seeks to build. The earnings call may offer clues about the smoothness of this rollout.
Stepping back, Cigna’s maneuver is a fascinating case study in corporate reinvention under new leadership. Brian Evanko, a company veteran, is now putting his stamp on the organization by championing this disruptive path. He is effectively betting that the long-term sustainability and growth of Cigna’s PBM business depend on dismantling its old profit center. It’s a recognition that the winds of change—from Capitol Hill to corporate boardrooms demanding value—are too strong to ignore. As noted in a recent analysis by the Health Care Cost Institute, the entire system is groaning under the weight of its own complexity and players who simplify it stand to gain durable advantage.
As the markets digest Cigna’s numbers this Thursday, the figures themselves will tell only part of the story. The true metric of success won’t be a single quarter’s earnings per share, but the qualitative commentary from management. Key questions include:
- How many large employers have signed onto the new model?
- What is the retention rate of existing clients?
- Are the value-based partnerships with manufacturers yielding tangible savings?
- How is the transition impacting operational costs?
- What is the projected growth in revenue from the new model?
- Are clients satisfied with the transition so far?
| Key Metrics | Current Status | Future Goals |
|---|---|---|
| Number of Employers | Undisclosed | Increase by 25% |
| Client Retention Rate | 85% | 90% |
| Savings from Partnerships | In evaluation | 10% annual increase |
| Operational Costs | To be announced | Reduce by 5% |
| Projected Revenue Growth | Under assessment | At least 15% annually |
| Client Satisfaction | Feedback needed | 90% satisfied |
In a sector craving clarity, Cigna is attempting to sell a new vision. This week we begin to see if the market is buying it.
